• 13 January, 2020

    ISSCR Hires New Director of Media and Strategic Communications

    The International Society for Stem Cell Research welcomes Kym Kilbourne as Director of Media and Strategic Communications, leading public affairs, education, member engagement, and media relations programs.
    Full story
      • 10 January, 2020

    Voting Now Open for 2020 Board of Directors

    Help to shape the future of your society by voting in the 2020 ISSCR Board of Directors election. Together, we offer a collaborative network and powerful resources to help members achieve personal objectives, foster the success of our field and contribute to the betterment of human health. This is your opportunity to make a difference.
    Full story
      • 9 January, 2020

    The ISSCR Hosts Ethics Workshop in China

    The ISSCR and the Guangzhou Institute of Biomedicine and Health held a two-day workshop in Guangzhou, China. A small group of scientists and ethicists from around the world met to discuss ethical, scientific, and societal challenges in regenerative medicine.
    Full story
      • 10 December, 2019

    ISSCR 2020 Boston: From Cutting Edge Technology to Clinical Trials

    There has been a convergence of technologies around stem cell research that are dramatically increasing our understanding of developmental biology, human disease, and how to regenerate damaged tissue. Cutting edge technological advancements in computational biology, machine learning, single cell sequencing, gene editing, and organoids are being harnessed by stem cell researchers to accelerate their discoveries and move them towards the clinic. These revolutionary advances will be in the spotlight from 24-27 June, 2020, at the largest stem cell meeting in the world— the ISSCR 2020 Annual Meeting in Boston, U.S.
    Full story
      • 9 December, 2019

    The ISSCR is Updating its Guidelines

    Stem cell science, its clinical application, and the ethical issues surrounding it have rapidly advanced since the release of the 2016 ISSCR Guidelines for Stem Cell Research and Clinical Translation. The latest update will address important scientific, ethical, and regulatory issues, including embryo models, organoids, chimeras, genome editing, and the regulation and economics of cell therapies.
    Full story
      • 11 November, 2019

    Activities of the ISSCR: More Than a Meeting

    The ISSCR Annual Meetings are the largest stem cell conferences in the world, known for featuring outstanding science. However, an underrecognized yet equally important aspect of the Society is its initiatives to advance the field. Behind the scenes, 22 Board Members, 15 committees, and other volunteers are working to develop and implement important initiatives and resources that enable, support, and promote excellence in stem cell science and its applications to human health.
    Full story
      • 10 October, 2019

    ISSCR Comments on Brazil’s Advanced Therapy Medicinal Products Regulation

    The ISSCR submitted comments to Brazil’s health regulatory agency (ANVISA) regarding the proposed regulations for advanced therapy medicinal products that urge national governments to “maintain rigorous review pathways to ensure that stem cell-based products conform to the highest standards of evidence-based medicine.”
    Full story
      • 8 October, 2019

    ISSCR Visits Capitol Hill, Washington, DC, U.S.

    The ISSCR led a group of scientists to Washington, DC, U.S. to garner support for policies important to stem cell research and the broader biomedical research community. The scientists met with representatives from 17 Congressional Offices to discuss the protection of fetal tissue research, the need for additional enforcement to curb the marketing and use of unproven products, and the importance of NIH funding for biomedical research.
    Full story
      • 8 October, 2019

    Lawrence Goldstein Policy Fellows Announced

    The ISSCR is pleased to announce the recipients of the inaugural Lawrence Goldstein Policy Fellowship, Mohamed Abou El-Enein, PhD (Charité Universitätsmedizin, Berlin, Germany) and Zubin Master, PhD (Mayo Clinic, Rochester, MN, U.S.).
    Full story
      • 7 October, 2019

    ISSCR Policy Advocacy in Action

    Polices created by legislators and regulators can have a profound impact on stem cell and biomedical research and the development of new treatments. The ISSCR has been working on several fronts to advocate for responsible stem cell research and its application. Read more about the recent ISSCR-led fly in to Washington D.C. for discussions with government officials and our consultations with Google to prevent the marketing of unproven stem cell therapies.
    Full story
      • 4 October, 2019

    ISSCR Education Committee Call for Resources

    The ISSCR Education Committee is compiling educational resources on stem cell science and its applications to support the teaching needs of our constituents. To help the Education Committee create the course syllabus, we are asking you for examples of your syllabi on courses related to stem cell biology, translational medicine, and clinical applications.
    Full story
      • 6 September, 2019

    ISSCR Applauds Google’s New Policy Banning Ads on Unproven Therapies

    The International Society for Stem Cell Research (ISSCR) today released the following statement regarding Google’s new policy that bans advertisements from unproven stem cell clinics and other speculative medical interventions.
    Full story
      • 22 August, 2019

    Nominate for ISSCR Awards and Leadership Positions

    The ISSCR is soliciting nominations to honor exceptional and innovative research and support for young scientists and the future of the field, through its extensive awards program. It also invites members to nominate candidates to serve on the ISSCR board of directors.
    Full story
      • 12 August, 2019

    The ISSCR Releases Informed Consent Standard for Stem Cell-based Interventions

    The International Society for Stem Cell Research (ISSCR) today released a professional standard of informed consent for stem cell-based interventions performed outside of formal clinical trials, such as the unapproved and unproven “treatments” offered by clinicians at direct-to-consumer clinics. The standard is meant to help ensure that patients are informed about the potential benefits and risks of stem cell-based medical interventions, and was developed with input from clinicians, ethicists, researchers, and regulators from around the world.
    Full story